ILD in Screening Study
Research type
Research Study
Full title
Interstitial lung disease within a lung cancer screening programme
IRAS ID
233809
Contact name
Nazia Chaudhuri
Contact email
Sponsor organisation
Research and Development
Duration of Study in the UK
1 years, 7 months, 2 days
Research summary
Research Summary
Interstitial lung disease (ILD) is a devastating lung condition with terrible outcomes. Lung cancer is the world’s leading cause of cancer related death. Unlike breast and bowel cancer, there is no national lung cancer screening programme; in Manchester we are piloting the UK's first lung cancer screening service. In addition to lung cancer, screening CT scans may pick up other lung conditions, including interstitial lung disease. This provides a unique opportunity to diagnose interstitial lung disease before the development of symptoms, when it might be possible to initiate treatment earlier and thereby improve patient outcomes.
We would like to determine how much (prevalence) interstitial lung disease is picked up in a lung cancer screening programme and how these cases compare to those diagnosed in the ‘standard’ way. We hypothesise that the patients diagnosed through screening will have an earlier stage of disease, less symptoms and be more suitable for disease modifying treatments.
Summary of Results
We found an Interstitial Lung Abnormality (ILA; a type of lung fibrosis change seen on a lung scan) was present in 3.9% in our lung cancer screening population, of which 40.7% were subsequently diagnosed with Interstitial Lung Disease (ILD; a type of lung scarring condition) within five years. Fibrotic ILA (a type of ILA) is a significant risk factor for progression to ILD and poorer outcomes, including mortality, at five years. Individuals with screen-detected ILA have less symptom burden and better health related quality of life in comparison to patients newly diagnosed with ILD through usual NHS channels/clinics.
REC name
West Midlands - Black Country Research Ethics Committee
REC reference
17/WM/0365
Date of REC Opinion
26 Sep 2017
REC opinion
Favourable Opinion